Hong Kong Champions of the AIA Healthiest Schools Competition 2024/25 - Baptist (Sha Tin Wai) Lui Ming Choi Primary School and Salesians of Don Bosco Ng Siu Mui Secondary School Win US$100,000 Prize and Advance to Regional Competition

HONG KONG SAR - Media OutReach Newswire - 20 June 2025 - AIA Hong Kong is pleased to announce that Baptist (Sha Tin Wai) Lui Ming Choi Primary School and Salesians of Don Bosco Ng Siu Mui Secondary School have been named the primary and secondary school winners, respectively, of the AIA Healthiest Schools Competition 2024/25 in Hong Kong. This year marks a significant milestone for the competition, as it has expanded to include secondary schools in Hong Kong for the first time. Participation has surged by over 60% compared to the previous cohort, setting a new record. Both winning schools excelled in their respective categories and will each receive a prize of US$50,000 to support their ongoing efforts in promoting a healthy campus. The winning schools will also advance to the Regional Competition, where they will compete against winners from Australia, Thailand, Vietnam, Indonesia, Malaysia, the Philippines and Sri Lanka for the title of Regional Winner. The results will be announced on 3 July.
Ms. Melissa Wong, Chief Customer and Marketing Officer of AIA Hong Kong and Macau, said, 'This year marks the third cohort of the AIA Healthiest Schools Programme, with a record-breaking number of entries and an exceptional standard of quality. This achievement reflects the unwavering dedication of Hong Kong schools to fostering healthy lifestyles among students. At AIA, we believe that cultivating healthy habits contributes significantly to societal well-being while supporting sustainable community development. We are committed to strengthening our collaboration with various stakeholders through this programme, empowering more individuals to live Healthier, Longer, Better Lives.'
Launched by AIA Group in 2022, the AIA Healthiest SchoolsProgramme provides free, expert-developed teaching resources that cover four themes: Healthy Eating, Active Lifestyles, Mental Well-being, and Health and Sustainability. The programme aims to foster healthy living habits among students, teachers and parents. Schools are also invited to participate in the AIA Healthiest Schools Competition, where they showcase their health programmes and achievements. Nearly 300 primary schools and secondary schools in Hong Kong, including publicly funded, direct-subsidy, private and international schools, have joined the AIA Healthiest Schools Programme since its launch.
Primary School Winner: Baptist (Sha Tin Wai) Lui Ming Choi Primary School
Embracing positive education, Baptist (Sha Tin Wai) Lui Ming Choi Primary School takes pride in a campus featuring vibrant murals and display boards with uplifting messages, and TV monitors showcasing students' accomplishments, all reflecting the joint efforts of the school, parents and students to promote positivity. The school offers 60 diverse well-being activities designed to build students' self-confidence and foster their holistic development. The daily 30-minute Energetic Recess aims to engage students in sports, followed by a whole-school exercise session to boost physical and mental well-being. Moreover, the school promotes sustainable living among students through farming, recycling, environmental conservation and animal interactions.
The school also engages parents in positive education and advocates for parent-child bonding through adventure camps and family gatherings. Certified parenting courses are arranged to encourage parents to share their experiences on positive education and co-create harmonious home environments. These initiatives help parents, students and teachers recognise and appreciate each student's strengths and talents, fostering self-confidence and unlocking their potential.
Baptist (Sha Tin Wai) Lui Ming Choi Primary School offers 60 diverse well-being activities designed to build students' self-confidence and foster their holistic development.
Secondary School Winner: Salesians of Don Bosco Ng Siu Mui Secondary School
Aiming to build a positive, well-being and healthy campus, Salesians of Don Bosco Ng Siu Mui Secondary School launched the Whole-Person Well-being Learning Experience (WLE) programme. This initiative empowers students to design and lead various activities that promote personal growth, deepen their appreciation of health and contribute to the community. The WLE framework has been expanded through the launch of 'Wellbeing Learning Dreamer: From WLE to WLD' project, where students participate in broader community engagement such as digital inclusion for seniors and art therapy, enabling them to apply the knowledge and practical skills to real-world community building.
Through the planning and execution of activities, students develop transferable skills that enhance their physical, mental, and social wellness while cultivating positive values and self-confidence. Between 2022 and 2025, over 70% of students participated in community service, contributing more than 4,000 service hours. The school also places strong emphasis on the wellbeing of teachers and parents through interactive activities such as regular positive psychology workshops, family outings, and sharing sessions. These efforts foster a culture of wellness that extends beyond the school campus, enriching families and the wider community.
Aiming to build a positive, well-being and healthy campus, Salesians of Don Bosco Ng Siu Mui Secondary School launched the Whole-Person Well-being Learning Experience (WLE) programme.
The AIA Healthiest Schools Programme forms part of the AIA One Billion initiative, which aims to engage a billion people to live Healthier, Longer, Better Lives by 2030. For details of the programme, please visit https://ahs.aia.com/hk/.
Hashtag: #AIA #友邦
The issuer is solely responsible for the content of this announcement.
About AIA Hong Kong & Macau
AIA Group Limited established its operations in Hong Kong in 1931. To date, AIA Hong Kong and AIA Macau have over 18,000 financial planners1, as well as an extensive network of independent financial advisors, brokerage and bancassurance partners. We serve over 3.6 million customers2, offering them a wide selection of professional services and products ranging from individual life, group life, accident, medical and health, pension, personal lines insurance to investment-linked assurance schemes with numerous investment options. We are also dedicated to providing superb product solutions to meet the financial needs of high-net-worth customers.
1 as at 31 March 2025
2 Including AIA Hong Kong and AIA Macau's individual life, group insurance and pension customers (as at 31 March 2025)

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Bloomberg

an hour ago

• Bloomberg

Chinese Biotech Showcases Challenger to Eli Lilly's Obesity Drug

An obesity drug from China helped patients lose a lot of weight in a late-stage clinical trial, making it a prospective new challenger to blockbusters from Novo Nordisk A/S and Eli Lilly & Co. Hangzhou Sciwind Biosciences Co. said its drug, ecnoglutide, led to more than 15% weight loss after 48 weeks when given at the highest dose. Although the trial did not compare ecnoglutide directly with existing medicines, the results were very similar to what Lilly's Zepbound showed in previous China studies, Sciwind Chief Executive Officer Hai Pan said in an interview.

Yahoo

8 hours ago

• Yahoo

New data from phase III trial confirms efficacy of Vyepti® (eptinezumab) in Asian population with chronic migraine

The full results of the phase III registrational SUNRISE trial were presented at the European Academy of Neurology 2025 Annual Congress, where eptinezumab demonstrated statistically significant reductions in mean monthly migraine days (MMDs) compared with placebo1 Patients receiving eptinezumab were four times more likely to achieve a reduction of ≥75% in MMDs within the first 4 weeks, compared to placebo1 The SUNRISE trial met all key secondary efficacy endpoints with improvements seen as early as day 1 and sustained through week 121 VALBY, Denmark, June 21, 2025 /PRNewswire/ -- H. Lundbeck A/S (Lundbeck) today announced the full results from the SUNRISE trial, a randomized, placebo-controlled trial designed to evaluate the efficacy and safety of eptinezumab versus placebo in a predominantly Asian population with chronic migraine. The study was presented at the 11th Congress of the European Academy of Neurology taking place in Helsinki 21-24 June.1 "Various treatments are recommended for patients with migraine in Asia, however utilization and adherence to migraine-specific treatment is relatively low. Access to effective treatments remains a significant unmet medical need for migraine prevention in Asia" said Johan Luthman, EVP and Head of R&D at Lundbeck. "The data from SUNRISE is consistent with previous results across diverse populations and will be pivotal for our efforts to expand access to eptinezumab for patients in Asia suffering with severe migraine." The double-blind, pivotal, SUNRISE trial (n=983) met all key primary and secondary endpoints, with eptinezumab demonstrating greater reductions in migraine frequency, the proportion of migraine attacks with severe pain, and disease burden, compared to placebo.1 "The SUNRISE trial marks a significant step forward in the mission to make migraine-specific preventive treatments more globally accessible, ensuring that patients with severe migraine receive the care they need" said Dr Patricia Pozo-Rosich, Head of Section of the Neurology Department, Director of Headache and Craniofacial Pain Clinical Unit and the Migraine Adaptive Brain Center at the Vall d'Hebron University Hospital in Barcelona, and principal investigator in the SUNRISE trial. In the SUNRISE trial, patients receiving eptinezumab experienced significantly fewer monthly migraine days (MMDs), with eptinezumab offering a -7.5 (300 mg) and -7.2 (100 mg) reduction in MMDs from week 1 through to 12, versus -4.8 with placebo (baseline MMD = 17, p<0.0001 for both 300 mg and 100 mg vs placebo).1 Amongst other parameters, patients receiving eptinezumab (300 mg or 100 mg) were four times more likely to achieve a reduction of ≥75% in the number of migraine days per month, compared to placebo within the first 4 weeks (p<0.0001).1 In the same study, eptinezumab also demonstrated a rapid onset of preventive efficacy, where more participants reported being free of migraine as early as day 1 after receiving eptinezumab treatment compared to placebo (p<0.002 for 300 mg dose; p<0.01 for 100 mg dose). This clinical efficacy was also reflected in patient reported outcomes where patients reported clinically meaningful improvements which were greater with eptinezumab than with placebo.1 Finally, the safety profile of eptinezumab was generally similar to placebo, previous trials, and to the current labelled safety information in the United States prescribing information and EU Summary of Product Characteristics, with the most common treatment-emergent adverse events being COVID-19 and nasopharyngitis.1 Based on the SUNRISE results, Lundbeck has initiated discussions with relevant regulatory authorities with the aim of making eptinezumab available for people suffering from migraine across Asia. About migraine Migraine is a complex and incapacitating neurological disease characterized by recurrent episodes of severe headaches typically accompanied by an array of symptoms, including nausea, vomiting, and sensitivity to light or sound. Not only is headache painful, but migraine also imposes both a social and financial burden. Migraine has a profound impact on patient functioning including relationships with family/friends, leisure activities, household production and worker productivity. Migraine is one of the most prevalent neurological diseases for which medical treatment is sought, and worldwide, is considered the leading cause of disability for people under the age of 50 and the 2nd leading cause of disability worldwide.3,4 Repeated headache attacks, and often the constant fear of the next one, damage family life, social life and work life. Furthermore, frequent use of acute migraine treatments may leave patients experiencing, or at risk of developing, medication overuse headache. Despite equally high prevalence of migraine in Asia as compared western countries, significant unmet needs remain in terms of sufficient and appropriate diagnosis, and better management and therapies for treatment of migraine in East Asia.5 In China, an estimated 14.3% of adults are living with migraine. From this population, approximately 52.9% will visit hospitals and only 13.8% of them will be diagnosed with migraine.6 About the SUNRISE trial SUNRISE (NCT04921384) is an interventional, multi-regional, multi-site, randomized, double-blind, placebo-controlled phase III trial, to confirm the efficacy and safety of eptinezumab in participants with chronic migraine who are eligible for preventive treatment.2 The study was conducted to support marketing authorization across Asia. Chronic migraine was defined as migraine occurring on ≥8 days per month and headache occurring on >14 days. Participants were randomly allocated to one of three treatment groups: eptinezumab 300 mg, eptinezumab 100 mg, or placebo. The double-blind, placebo-controlled treatment period was followed by an extension period where all participants received active treatment to further assess the safety and tolerability of eptinezumab. The total trial duration from the Screening Visit to the Safety Follow-up Visit is approximately 36 weeks and includes a Screening Period (28-30 days), a Placebo-controlled Period (12 weeks), an Extension Period (12 weeks), and a Safety Follow-up Period (8 weeks).1 Participants in Japan completing the SUNRISE trial were offered to continue in the SUNSET trial (NCT05064371) which consisted of an open-label eptinezumab treatment of 60 weeks (five infusions), and a Safety Follow-up Period (8 weeks). The SUNRISE was initiated in May 2021 and was conducted in Mainland China, Georgia, Japan, Poland, Slovakia, South Korea, Spain and Taiwan. In the trial, 983 participants were randomized to receive eptinezumab 100 mg or 300 mg or placebo by intravenous (IV) infusion.2 About Vyepti® (eptinezumab) Eptinezumab is a humanized monoclonal antibody that binds to calcitonin gene-related peptide (CGRP) which was intentionally designed for IV administration. The efficacy and safety of eptinezumab was evaluated in two phase III clinical trials (PROMISE-1 in episodic migraine7 and PROMISE-2 in chronic migraine8), where eptinezumab met its primary endpoint of decrease in MMDs over weeks 1-12 in both episodic and chronic migraine. Furthermore, the clinical trial program demonstrated a treatment benefit over placebo that was observed for both doses of eptinezumab as early as day 1 post-infusion. The safety of eptinezumab was evaluated in more than 2,000 adult patients with migraine who received at least one dose of eptinezumab. The most common adverse reactions (≥2% and at least 2% or greater than placebo) in the clinical trials for the preventive treatment of migraine were nasopharyngitis and hypersensitivity. In PROMISE-1 and PROMISE-2, 1.9% of patients treated with eptinezumab discontinued treatment due to adverse reactions. Vyepti® (eptinezumab-jjmr) was approved by the U.S. Food and Drug Administration (FDA) for the preventive treatment of migraine in adults in February 2020, and in January 2022, eptinezumab was granted marketing authorization by the European Commission (EC) for the prophylaxis of migraine in adults who have at least four migraine days per month. Today, eptinezumab is launched in more than 30 markets worldwide. Contacts Marie Petterson Jens Høyer Head of Media Relations, Corp. Communication Vice President, Head of Investor Relations MEEP@ JSHR@ +45 29 82 21 82 +45 30 83 45 01Palle Holm OlesenVice President, Investor RelationsPALO@ 30 83 24 26 About H. Lundbeck A/S Lundbeck is a biopharmaceutical company focusing exclusively on brain health. With more than 70 years of experience in neuroscience, we are committed to improving the lives of people with neurological and psychiatric diseases. Brain disorders affect a large part of the world's population, and the effects are felt throughout society. With the rapidly improving understanding of the biology of the brain, we hold ourselves accountable for advancing brain health by curiously exploring new opportunities for treatments. As a focused innovator, we strive for our research and development programs to tackle some of the most complex neurological challenges. We develop transformative medicines targeting people for whom there are few or no treatments available, expanding into neuro-specialty and neuro-rare from our strong legacy within psychiatry and neurology. We are committed to fighting stigma and we act to improve health equity. We strive to create long term value for our shareholders by making a positive contribution to patients, their families and society as a whole. Lundbeck has approximately 5,700 employees in more than 50 countries and our products are available in more than 80 countries. For additional information, we encourage you to visit our corporate site and connect with us via LinkedIn. References: Yu S, ePresentation at EAN Congress 2025 H. Lundbeck A/S. Eptinezumab as Preventive Treatment of Migraine in Adults With Migraine (Sunrise). NCT04921384 Steiner TJ, Stovner LJ, Vos T. et al. J Headache Pain 2018; 19: 17. Leonardi M, Steiner TJ, Scher AT, Lipton RB. J Headache Pain. 2005; 6(6): 429– 440. Takeshima, T, et al. J Headache Pain 2019; 20, 111 Guidelines for the diagnosis and treatment of migraine in China (2022 edition). Chinese Journal of Pain Medicine 2022, 28 (12) Ashina M, et al. Cephalalgia. 2020 Mar;40(3):241-254. Lipton RB, et al. Neurology. 2020 Mar 31;94(13):e1365-e1377. CONTACT: H. Lundbeck A/SOttiliavej 9, 2500 Valby, Denmark+45 3630 1311info@ This information was brought to you by Cision The following files are available for download: EAN 2025 Press Release SUNRISE_Final View original content:

Yahoo

16 hours ago

• Yahoo

Alcohol linked to increased risk of pancreatic cancer: Study

Alcoholic beverages, particularly beer and spirits, may increase the risk of developing pancreatic cancer, according to a new study led by the UN World Health Organization. The research, which pooled data from nearly 2.5 million people across Asia, Australia, Europe and North America, revealed a 'modest but significant' link between alcohol consumption and pancreatic cancer risk, regardless of sex or smoking status. 'Alcohol consumption is a known carcinogen, but until now, the evidence linking it specifically to pancreatic cancer has been considered inconclusive,' said Pietro Ferrari, senior author of the study and head of the nutrition and metabolism branch at the World Health Organization International Agency for Research on Cancer. The study revealed that each additional 10 grams of alcohol consumed per day was associated with a three percent increase in pancreatic cancer risk. Additionally, women consuming 15-30 grams of alcohol daily, which equates to about one to two drinks, had a 12 percent higher risk. Men drinking 30-60 grams daily had a 15 percent increased risk, increasing to 36 percent for those consuming more than 60 grams. The study confirmed alcohol as an 'independent risk factor,' even after accounting for smoking. Ferrari emphasized that 'alcohol is often consumed in combination with tobacco,' but the elevated risk persists among non-smokers. Pancreatic cancer, a disease that impacts digestive enzyme production and blood sugar regulation, remains one of the deadliest cancers due to late-stage diagnoses. Although it ranks 12th in global cancer incidence, it accounts for 5 percent of all cancer-related deaths, according to the WHO. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.